



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Buprenorphine - Med Assisted Treatment Renewal

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with fields for Patient Name, HPP Member Number, Date of Birth, Address, City, State ZIP, Patient Primary Phone, Line of Business (Medicaid, CHIP), Prescriber Name, Fax, Phone, Office Contact, NPI, Promise ID, Prescriber PA PROMISe ID, Address, City, State ZIP, Specialty/facility name (if applicable).

Expedited/Urgent checkbox

Drug Name:

Strength:

Days Supply:

Number of Refills:

Directions / SIG:

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Has the patient been previously approved for treatment with buprenorphine for medication assisted treatment? * Please note, prescriptions for buprenorphine-naloxone or buprenorphine tablet at a dose of 16 mg per day is available without prior authorization.

Yes checkbox

No checkbox

Q2. Is the requested medication injectable extended release buprenorphine?

Yes checkbox

No checkbox

Q3. Has documentation been attached (i.e. chart notes) confirming that the patient has achieved positive clinical response on treatment with extended release injectable buprenorphine?

Yes checkbox

No checkbox

Q4. Does the patient require supplemental doses of oral buprenorphine?

Yes checkbox

No checkbox

Q5. Has documentation been attached including the reason why the patient requires continued treatment with a non-preferred buprenorphine-naloxone preparation and a plan to transition the patient to buprenorphine-naloxone tablets, if applicable?

Yes checkbox

No checkbox

Q6. Is the dose being prescribed greater than 16 mg per day and/or the previously prescribed dose?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Buprenorphine - Med Assisted Treatment Renewal

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Yes checkbox

No checkbox

Q7. Is there documentation attached showing therapeutic failure at a dose of 16 mg/day and/or the previously approved dose as well as documentation of the prescriber's treatment and monitoring plan...

Yes checkbox

No checkbox

Q8. Have non-pharmacologic treatment options, including additional counseling and substance abuse related behavioral treatment services been utilized to address treatment failure with previous dose of buprenorphine prior to initiating an increase in dose?

Yes checkbox

No checkbox

Q9. Has the patient demonstrated compliance with buprenorphine therapy as evidenced by recent urine drug screen positive for both buprenorphine and norbuprenorphine AND negative for opioids...

Yes checkbox

No checkbox

Q10. Is there a documented plan attached to address the findings of the urine drug screen? Documentation must be attached.

Yes checkbox

No checkbox

Q11. Is there documentation of continued participation in a substance abuse or behavioral health (BH) treatment program, BH counseling, or an addictions recovery program? During the initial course of treatment, referral and enrollment must be with a licensed Drug and Alcohol (D&A) or BH provider...

Yes checkbox

No checkbox

Q12. Has the prescriber checked the patient's prescription history in the Prescription Drug Monitoring Program (PDMP)?

Yes checkbox

No checkbox

Q13. Requested Duration:

6 Months checkbox

Q14. Additional Information:

Prescriber Signature

Date



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Buprenorphine - Med Assisted Treatment Renewal

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Updated 2018